In Brief: Biomira/Neoprobe Corp.
This article was originally published in The Gray Sheet
Biomira/Neoprobe Corp.: Firms ink agreement under which Neoprobe gains exclusive worldwide rights to use Biomira's radiolabeled urine monoclonal antibody Mab-170 in its RIGS hand-held, gamma-detecting probe technology "for surgical detection of breast cancer." Neoprobe plans to commence Phase I trials with the MAb-170/RIGS device with up to 45 women undergoing breast-conserving surgery. In return, Biomira receives an upfront fee from Neoprobe, as well as milestone payments and royalties "upon commercialization of a RIGS product using MAb-170." Under the deal, Neoprobe also obtains rights to: the MAb-170/RIGS technology for other clinical indications; any enhancements to the MAb-170 antibody; and an option to license another Biomira antibody, MAb-174...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.